Biopharma

RTSN

1 brief covering RTSN, most recent first.

  1. · IPO priced

    RTSN — IPO pricing analysis (2026-10-10)

    | **Lead asset** | RTN-001, oral PDE-5 inhibitor for resistant/refractory hypertension |

    Read brief →